These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21397718)

  • 81. Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development.
    Torisu T; Shikama S; Nakamura K; Enomoto K; Maruno T; Mori A; Uchiyama S; Satou T
    J Pharm Sci; 2021 May; 110(5):2121-2129. PubMed ID: 33340531
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Role of phenol red in the stabilization of the Sabin type 2 inactivated polio vaccine at various pH values.
    Huijuan Y; Xiaohu D; Ze L; Wei C; Jian Z; Lei M; Shaohui S; Weidong L; Guoyang L
    J Med Virol; 2019 Jan; 91(1):22-30. PubMed ID: 30133803
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Development of a fast ELISA for quantifying polio D-antigen in in-process samples.
    ten Have R; Thomassen YE; Hamzink MR; Bakker WA; Nijst OE; Kersten G; Zomer G
    Biologicals; 2012 Jan; 40(1):84-7. PubMed ID: 22154015
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Poliovirus neutralization test with poliovirus pseudovirus to measure neutralizing antibody in humans.
    Arya SC; Agarwal N
    Clin Vaccine Immunol; 2012 Mar; 19(3):458; author reply 459. PubMed ID: 22371252
    [No Abstract]   [Full Text] [Related]  

  • 85. Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines.
    Morgeaux S; Milne C; Daas A
    Pharmeuropa Bio; 2005 Sep; 2005(1):19-26. PubMed ID: 16336935
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Preformulation study of highly purified inactivated polio vaccine, serotype 3.
    Qi W; Zeng Y; Orgel S; Francon A; Kim JH; Randolph TW; Carpenter JF; Middaugh CR
    J Pharm Sci; 2014 Jan; 103(1):140-51. PubMed ID: 24282078
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antibody titer to the poliovirus in blood and cerebrospinal fluid of patients with post-polio syndrome.
    Jubelt B; Salazar-Grueso EF; Roos RP; Cashman NR
    Ann N Y Acad Sci; 1995 May; 753():201-7. PubMed ID: 7611629
    [No Abstract]   [Full Text] [Related]  

  • 88. [Diagnosis of polio-virus infections].
    Jansen P
    Naturwissenschaften; 1974 Jun; 61(6):276. PubMed ID: 4368106
    [No Abstract]   [Full Text] [Related]  

  • 89. Complete genome sequences of six S19 poliovirus reference strains.
    Castro CJ; Wiese N; Bullows JE; Poston KD; Meade C; Jorba J; Mainou BA
    Microbiol Resour Announc; 2024 Jul; 13(7):e0008024. PubMed ID: 38888364
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Development of a Genetically-Engineered, Candidate Polio Vaccine Employing the Self-Assembling Properties of the Tobacco Mosaic Virus Coat Protein.
    Haynes JR; Cunningham J; von Seefried A; Lennick M; Garvin RT; Shen SH
    Biotechnology (N Y); 1986; 4(7):637-641. PubMed ID: 32226216
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dr. Florence Rena Sabin (1871-1953): Remaking the Face of Medicine.
    Hall AD; Kumar JE
    J Med Biogr; 2023 Oct; ():9677720231198504. PubMed ID: 37787177
    [No Abstract]   [Full Text] [Related]  

  • 92. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.
    Kumar P; Bird C; Holland D; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Dec; 18(7):2154100. PubMed ID: 36576132
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Development of an animal component free production process for Sabin inactivated polio vaccine.
    Suarez-Zuluaga DA; van der Pol LA; van 't Oever AG; Bakker WAM; Thomassen YE
    Vaccine X; 2022 Dec; 12():100223. PubMed ID: 36217423
    [TBL] [Abstract][Full Text] [Related]  

  • 95. In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine.
    Abd-Elghaffar AA; Rashed ME; Ali AE; Amin MA
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33066050
    [TBL] [Abstract][Full Text] [Related]  

  • 96. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.
    Wan Y; Hickey JM; Bird C; Witham K; Fahey P; Forster A; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Jun; 107(6):1540-1551. PubMed ID: 29421219
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Biosensor binding data and its applicability to the determination of active concentration.
    Karlsson R
    Biophys Rev; 2016 Dec; 8(4):347-358. PubMed ID: 28510014
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.